Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2003

View Archived Issues

CBT-1008 manufactured for preclinical studies

PVAC development for psoriasis discontinued

Approvable letter for Inspire's diquafosol tetrasodium ophthalmic solution

Novacea stops enrollment in DN-101 trial for MDS

Canadian notice of noncompliance for Statex

CPMP rejects PharmaMar appeal regarding Yondelis

Connetics submits NDA for Actiza

Eisai submits MAA for rapid dissolve Aricept in U.K.

GTI-2501 enters phase II

Sixteenth Medarex fully human antibody enters clinical development

Pivotal urban ambulance trial cleared to begin for PolyHeme(R)

PMA filing commences for OrCel for venous leg ulcers

Phase III doripenem trial commences enrollment

Enrollment completed in phase IIa study of PCK-3145

European orphan drug designation for gimatecan for glioma

Topical tacrolimus reported effective for oral lichen planus and facial psoriasis

Potential clinical benefits of CAI in ovarian cancer

France is first country to approve oral thrombin inhibitor

Series of phosphonates able to modulate apolipoprotein E described by Ilex

New stimulators of guanylate cyclase described in Bayer patent

New King Pharmaceuticals patent claims adenosine A3 receptor antagonists

Broad spectrum antiparasitics prepared at the University of Mississippi

Otsuka describes novel thiourea derivatives for diabetes and obesity

Tributyrin induces apoptosis of leukemia cell lines

FR-181157 shows potent PGI2 agonist activity and good pharmacokinetic profile

JNJ-10329670 represents a new class of immunosuppressive compounds

Health officials prepare for SARS resurgence, review treatment options

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...